Novo Nordisk raised full-year guidance on stronger-than-expected uptake of its Wegovy pill, while GSK secured a $1 billion siRNA deal with China's SiranBio targeting cardiometabolic disease. Bayer announced its largest acquisition in years, agreeing to buy Perfuse Therapeutics for up to $2.45 billion to bolster its eye drug pipeline, and Avalo Therapeutics posted positive Phase 2 data in inflammatory skin disease while raising $375 million to advance development.
Top Stories
Novo Nordisk Raises Guidance on Strong Wegovy Pill Launch
Novo Nordisk elevated its full-year financial guidance after its oral semaglutide obesity pill posted stronger-than-anticipated early prescription volumes, according to BioPharma Dive and STAT. The Danish drugmaker now expects sales and profit to shrink less than originally forecast, with CEO Mike Doustdar separately noting the company is more active than ever in seeking deals. This signals confidence that oral GLP-1 formulations can sustain commercial momentum despite intensifying competition in the obesity space.
Bayer to Acquire Perfuse Therapeutics for Up to $2.45B in Eye Drug Push
Bayer agreed to acquire Perfuse Therapeutics for up to $2.45 billion ($300 million upfront plus development, regulatory, and commercial milestones), gaining lead asset PER-001 — a Phase 2 endothelin receptor antagonist being developed for both glaucoma and diabetic retinopathy — and strengthening its ophthalmology pipeline, BioPharma Dive and PharmExec reported. The transaction represents Bayer's first drug company acquisition in several years and its largest since purchasing AskBio in 2020. The move suggests Bayer is rebuilding its specialty pharma portfolio after years of pipeline setbacks and divestments.
GSK Licenses SiranBio's siRNA Drug in $1B Cardiometabolic Deal
GSK deepened its cardiometabolic pipeline by securing rights to an ALK7-targeted siRNA therapy from China's SiranBio in a deal worth up to $1 billion in biobucks, Endpoints News and pharmaphorum reported. The Suzhou-based startup's candidate operates in the same obesity-adjacent space as Arrowhead's programs, and the agreement continues GSK's strategy of accessing Chinese innovation while diversifying beyond its traditional respiratory and vaccine franchises. Worth watching because ALK7 modulation remains clinically unproven at scale in metabolic disease.
Avalo Posts Phase 2 Win for Abdakibart in Hidradenitis Suppurativa, Prices $375M Offering
Avalo Therapeutics reported that its anti-IL-1β/IL-1α dual antagonist abdakibart met the primary endpoint at both doses in the Phase 2 LOTUS trial in moderate-to-severe hidradenitis suppurativa — with both arms achieving HiSCR75 of approximately 42% at Week 16 versus 25.6% for placebo — and simultaneously priced a $375 million public offering, per Endpoints News and a company release via GlobeNewswire. The mid-stage data and capital raise position Avalo to advance abdakibart into Phase 3. This signals renewed investor appetite for differentiated immunology assets with clear clinical proof-of-concept.
CellCentric Secures $220M Series D to Fund Myeloma Pivotal Trials
CellCentric raised $220 million in Series D financing to support pivotal development of p300/CBP inhibitor inobrodib in multiple myeloma, pharmaphorum reported. The blood cancer program targets an epigenetic mechanism distinct from existing myeloma therapies, and the substantial capital raise reflects confidence in differentiated mechanisms of action for hematologic malignancies. The move suggests institutional investors are backing novel modalities beyond the crowded BTK and CAR-T spaces.
Former Orbital Scientists Launch ParcelBio With $13M for mRNA Delivery
Two former Orbital Therapeutics scientists launched ParcelBio with $13 million in seed funding, claiming to have solved a technical problem limiting the mRNA revolution's reach, according to Endpoints News. The startup aims to develop mRNA drugs leveraging proprietary delivery technology that could expand applications beyond vaccines and liver-targeted therapies. Worth watching because delivery remains the key bottleneck preventing broader mRNA therapeutic applications.
Zentalis Doses First Patient in Phase 3 ASPENOVA Trial of Azenosertib in Ovarian Cancer
Zentalis Pharmaceuticals announced first patient dosing in its Phase 3 ASPENOVA trial evaluating azenosertib in patients with Cyclin E1-positive platinum-resistant ovarian cancer, PharmExec reported, with additional details available via BioSpace. The randomized, confirmatory study (NCT07546500, GOG-3147, ENGOT-ov109) is designed to support full approval of the WEE1 inhibitor and is being conducted in collaboration with the GOG Foundation, ENGOT, and APGOT. This signals progress for cell cycle kinase inhibitors in solid tumors after years of mixed clinical results in the target class.
What to Watch
- Oral GLP-1 trajectory — Novo's raised guidance suggests the Wegovy pill is capturing share faster than anticipated; competitive response from Lilly and emerging players will determine whether oral formulations expand or cannibalize the injectable obesity market.
- China biotech partnerships — GSK's SiranBio deal follows a pattern of Western pharma licensing early-stage innovation from Chinese startups; watch for geopolitical or regulatory friction as these agreements proliferate.
- Epigenetic oncology — CellCentric's $220M raise for p300/CBP inhibition in myeloma reflects renewed interest in chromatin modulators; pivotal data could reopen investor enthusiasm for epigenetic targets beyond HDACs and EZH2.
- mRNA delivery innovation — ParcelBio's claim to solve a core delivery problem warrants scrutiny; if validated, could unlock extrahepatic mRNA applications in CNS, lung, and muscle tissue.
Market Snapshot
- Obesity market maturation: Novo's guidance raise on oral Wegovy demonstrates the GLP-1 category is evolving beyond injectables, with oral formulations now commanding significant prescription volume within months of launch.
- Biopharma M&A activity: Bayer's $2.45B Perfuse acquisition and GSK's $1B SiranBio licensing deal suggest large-cap pharma are deploying capital aggressively to fill mid-stage pipelines in specialty therapeutic areas.
- Hematology financing strength: CellCentric's $220M Series D for a myeloma program indicates sustained investor confidence in differentiated blood cancer assets with novel mechanisms, despite broader biotech financing challenges.
